# Frontier Medicines

Source: https://onco.cc/companies/frontier-medicines/  
OnCo record `frontier-medicines` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Chemoproteomics company with FMC-376, a KRAS G12C inhibitor that hits both the ON and OFF states of the protein, in phase 1/2.

## Summary

Frontier Medicines, based in South San Francisco, is a chemoproteomics company whose FMC-376, a KRAS G12C inhibitor that hits both the ON and OFF states of the protein, is in phase 1/2. FMC-376 covalently targets GTP-bound and GDP-bound KRAS G12C and is designed to overcome the adaptive receptor tyrosine kinase feedback that limits first-generation G12C drugs; the PROSPER phase 1/2 trial, NCT06244771, is recruiting with primary completion estimated for October 2027. OnCo links it to non-small-cell lung, colorectal and pancreatic cancer, to KRAS and RAS inhibitors, to KRAS as a target and the MAPK pathway, to the bottleneck of undruggable drivers, and to ideas on covalent chemistry for RAS mutations and an open map of which proteins any drug can bind. Whether dual-state inhibition delays resistance in patients is the question PROSPER will answer. The KRAS target page carries the field.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: South San Francisco, CA
- Type: biotech
- Website: https://www.frontiermeds.com

## Sources

- PROSPER trial: https://clinicaltrials.gov/study/NCT06244771

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- pathways: [RAS / RAF / MEK / ERK (MAPK)](https://onco.cc/pathways/ras-mapk/)
- trials: [A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors](https://onco.cc/trials/nct06244771/)
- bottlenecks: [The undruggable drivers](https://onco.cc/bottlenecks/b-undruggable-targets/)
- ideas: [An open map of which cancer proteins any drug can stick to](https://onco.cc/ideas/idea-bio1-covalent-ligandability-atlas/), [Covalent chemistry for the RAS mutations that still have no drug](https://onco.cc/ideas/idea-bio1-pan-ras-covalent-g12d/)
- companies: [MPM BioImpact](https://onco.cc/companies/mpm-bioimpact/)
- roadmaps: [Drug discovery roadmap: screening in mice → maps of dependency → designing in silico](https://onco.cc/roadmaps/drug-discovery-roadmap/), [Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall](https://onco.cc/roadmaps/targeted-therapy-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/frontier-medicines.json